Haemonetics
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$59.46
FAIR PRICE
$57.65
MARGIN
$1.81
NOW AVAILABLE
Get notified when HAE's fair price changes
Push notifications when HAE's valuation shifts. Available on iOS and Android.
FPI RATING
Strong profitability and attractive valuation, but elevated debt levels and volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$46.12
Fair price × 0.80
DISTANCE
22.4%
Price to entry level
At the current price of $59.46, HAE trades 22.4% above the conservative entry level of $46.12. This entry level represents a 20% margin of safety below the calculated fair price of $57.65 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate HAE's fair price
Haemonetics's fair price of $57.65 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $59.46, HAE trades 3.0% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting HAE's risk profile.
RELATIVE · 30%
Comparing HAE's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for HAE, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate HAE's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for HAE.
Explore on BuliosFAQ
What is the fair price of HAE?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Haemonetics is $57.65. At the current market price of $59.46, HAE trades 3.0% above its calculated fair value.
Is HAE overvalued or undervalued?+
Haemonetics is currently fair based on our valuation model. The stock trades at $59.46, which is 3.0% above the fair price of $57.65. The P/E ratio of 18.0x is a key metric in the valuation.
What is the margin of safety for HAE?+
With a 20% margin of safety applied to the fair price of $57.65, the conservative entry level for HAE is $46.12. At the current market price of $59.46, the stock trades 22.4% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is HAE's fair price updated?+
We update fair price calculations for HAE daily after market close. The current fair price of $57.65 incorporates the latest market data and sector multiples.
What factors affect HAE's fair price calculation?+
HAE's fair price of $57.65 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 18.0x, ROE of 18.7%.
Is HAE a good buy right now?+
At $59.46, HAE trades 3.0% above our fair value estimate of $57.65. The stock is currently fair. ROE stands at 18.7% (strong). Fair Price Index provides valuation data — always do your own research before investing.
Does HAE pay dividends?+
HAE does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.